Junayed Nayeen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junayed Nayeen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adrianne Wallace-Povirk
Department of Oncology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
42 shared publications - Aleem Gangjee
Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States
42 shared publications - Larry H. Matherly
Department of Oncology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
42 shared publications - Zhanjun Hou
Karmanos Cancer Institute, Detroit, Michigan, United States
42 shared publications - Aamod S. Dekhne
Department of Oncology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
41 shared publications - Lisa Polin
Department of Oncology Wayne State University School of Medicine 48201 Detroit MI
40 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows results of apoptosis assays with SKOV3 cells treated with AGF347.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows results of apoptosis assays with SKOV3 cells treated with AGF347.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows generation of SKOV3 SHMT1 and SHMT2 knockdown (KD) cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows generation of SKOV3 SHMT1 and SHMT2 knockdown (KD) cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows primer sequences for quantitative real-time RT-PCR.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows primer sequences for quantitative real-time RT-PCR.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows information of epithelial ovarian cancer tissue microarray (TMA) for immunohistochemistry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows information of epithelial ovarian cancer tissue microarray (TMA) for immunohistochemistry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows purification of the recombinant human thymidylate synthase (TS) and in vitro inhibition by pyrrolo[3,2-d]pyrimidine antifolates.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows purification of the recombinant human thymidylate synthase (TS) and in vitro inhibition by pyrrolo[3,2-d]pyrimidine antifolates.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S6 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows Kis for inhibition of one-carbon enzymes for 5-substituted pyrrolo[3,2- d]pyrimidine antifolates.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S6 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows Kis for inhibition of one-carbon enzymes for 5-substituted pyrrolo[3,2- d]pyrimidine antifolates.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows IC50 values for antiproliferative activities toward EOC versus normal ovary cell lines by 5-substituted pyrrolo[3,2-d]pyrimidine inhibitors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows IC50 values for antiproliferative activities toward EOC versus normal ovary cell lines by 5-substituted pyrrolo[3,2-d]pyrimidine inhibitors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows FRα, PCFT and RFC expression in EOC cell line models and EOC patient cDNAs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This figure shows FRα, PCFT and RFC expression in EOC cell line models and EOC patient cDNAs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows purity of Subcellular Fractions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows purity of Subcellular Fractions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows information of ovarian cancer tissue cDNA array for real-time RT-PCR.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer
This table shows information of ovarian cancer tissue cDNA array for real-time RT-PCR.